Amr E Abbas1, Laura M Franey2, Thomas Marwick3, Micha T Maeder4, David M Kaye5, Antonios P Vlahos6, Walter Serra7, Karim Al-Azizi8, Nelson B Schiller9, Steven J Lester10. 1. Department of Cardiology, Beaumont Health System, Royal Oak, Michigan; Oakland University/William Beaumont School of Medicine, Rochester, Michigan. 2. Department of Cardiology, Beaumont Health System, Royal Oak, Michigan. Electronic address: aabbas@beaumont.edu. 3. Menzies Research Institute of Tasmania, Hobart, Australia. 4. Baker IDI Heart and Diabetes Institute, Melbourne, Australia; Heart Center, Alfred Hospital, Melbourne, Australia; Cardiology Division, Kantonsspital St. Gallen, St. Gallen, Switzerland. 5. Baker IDI Heart and Diabetes Institute, Melbourne, Australia; Heart Center, Alfred Hospital, Melbourne, Australia. 6. Pediatric Cardiology Division, University of Ioannina, Ioannina, Greece. 7. Cardiopulmonary Department, University Hospital, Parma, Italy. 8. Department of Internal Medicine, St. Joseph Mercy Oakland, Pontiac, Michigan. 9. University of San Francisco, San Francisco, California. 10. Division of Cardiovascular Diseases, Mayo Clinic, Scottsdale, Arizona.
Abstract
BACKGROUND: The ratio of tricuspid regurgitation velocity (TRV) to the time-velocity integral of the right ventricular outflow tract (TVIRVOT) has been studied as a reliable measure to distinguish elevated from normal pulmonary vascular resistance (PVR). The equation TRV/TVIRVOT × 10 + 0.16 (PVRecho) has been shown to provide a good noninvasive estimate of PVR. However, its role in patients with significantly elevated PVR (> 6 Wood units [WU]) has not been conclusively evaluated. The aim of this study was to establish the validity of the TRV/TVIRVOT ratio as a correlate of PVR. The role of TRV/TVIRVOT was also compared with that of a new ratio, TRV(2)/TVIRVOT, in patients with markedly elevated PVR (>6 WU). METHODS: Data from five validation studies using TRV/TVIRVOT as an estimate of PVR were compared with invasive PVR measurements (PVRcath). Multiple linear regression analyses were generated between PVRcath and both TRV/TVIRVOT and TRV(2)/TVIRVOT. Both PVRecho and a new derived regression equation based on TRV(2)/TVIRVOT: 5.19 × TRV(2)/TVIRVOT - 0.4 (PVRecho2) were compared with PVRcath using Bland-Altman analysis. Logistic models were generated, and cutoff values for both TRV/TVIRVOT and TRV(2)/TVIRVOT were obtained to predict PVR > 6 WU. RESULTS: One hundred fifty patients remained in the final analysis. Linear regression analysis between PVRcath and TRV/TVIRVOT revealed a good correlation (r = 0.76, P < .0001, Z = 0.92). There was a better correlation between PVRcath and TRV(2)/TVIRVOT (r = 0.79, P < .0001, Z = -0.01) in the entire cohort as well as in patients with PVR > 6 WU. Moreover, PVRecho2 compared better with PVRcath than PVRecho using Bland-Altman analysis in the entire cohort and in patients with PVR > 6 WU. TRV(2)/TVIRVOT and TRV/TVIRVOT both predicted PVR > 6 WU with good sensitivity and specificity. CONCLUSIONS: TRV/TVIRVOT is a reliable method to identify patients with elevated PVR. In patients with TRV/TVIRVOT > 0.275, PVR is likely > 6 WU, and PVRecho2 derived from TRV(2)/TVIRVOT provides an improved noninvasive estimate of PVR compared with PVRecho.
BACKGROUND: The ratio of tricuspid regurgitation velocity (TRV) to the time-velocity integral of the right ventricular outflow tract (TVIRVOT) has been studied as a reliable measure to distinguish elevated from normal pulmonary vascular resistance (PVR). The equation TRV/TVIRVOT × 10 + 0.16 (PVRecho) has been shown to provide a good noninvasive estimate of PVR. However, its role in patients with significantly elevated PVR (> 6 Wood units [WU]) has not been conclusively evaluated. The aim of this study was to establish the validity of the TRV/TVIRVOT ratio as a correlate of PVR. The role of TRV/TVIRVOT was also compared with that of a new ratio, TRV(2)/TVIRVOT, in patients with markedly elevated PVR (>6 WU). METHODS: Data from five validation studies using TRV/TVIRVOT as an estimate of PVR were compared with invasive PVR measurements (PVRcath). Multiple linear regression analyses were generated between PVRcath and both TRV/TVIRVOT and TRV(2)/TVIRVOT. Both PVRecho and a new derived regression equation based on TRV(2)/TVIRVOT: 5.19 × TRV(2)/TVIRVOT - 0.4 (PVRecho2) were compared with PVRcath using Bland-Altman analysis. Logistic models were generated, and cutoff values for both TRV/TVIRVOT and TRV(2)/TVIRVOT were obtained to predict PVR > 6 WU. RESULTS: One hundred fifty patients remained in the final analysis. Linear regression analysis between PVRcath and TRV/TVIRVOT revealed a good correlation (r = 0.76, P < .0001, Z = 0.92). There was a better correlation between PVRcath and TRV(2)/TVIRVOT (r = 0.79, P < .0001, Z = -0.01) in the entire cohort as well as in patients with PVR > 6 WU. Moreover, PVRecho2 compared better with PVRcath than PVRecho using Bland-Altman analysis in the entire cohort and in patients with PVR > 6 WU. TRV(2)/TVIRVOT and TRV/TVIRVOT both predicted PVR > 6 WU with good sensitivity and specificity. CONCLUSIONS: TRV/TVIRVOT is a reliable method to identify patients with elevated PVR. In patients with TRV/TVIRVOT > 0.275, PVR is likely > 6 WU, and PVRecho2 derived from TRV(2)/TVIRVOT provides an improved noninvasive estimate of PVR compared with PVRecho.
Authors: Laila M Elmaghawry; Ibtesam I El-Dosouky; Nader T Kandil; Ahmad Mohammad Sayyid-Ahmad Sayyid-Ahmad Journal: Int J Cardiovasc Imaging Date: 2017-10-30 Impact factor: 2.357
Authors: Martin Koestenberger; Mark K Friedberg; Eirik Nestaas; Ina Michel-Behnke; Georg Hansmann Journal: Pulm Circ Date: 2016-03 Impact factor: 3.017
Authors: Martin Koestenberger; Bert Nage; William Ravekes; Alexander Avian; Ante Burmas; Gernot Grangl; Gerhard Cvirn; Andreas Gamillscheg Journal: Pediatr Cardiol Date: 2015-03-06 Impact factor: 1.655
Authors: Vitaly O Kheyfets; Michal Schafer; Chris A Podgorski; Joyce D Schroeder; James Browning; Jean Hertzberg; J Kern Buckner; Kendal S Hunter; Robin Shandas; Brett E Fenster Journal: J Magn Reson Imaging Date: 2016-05-13 Impact factor: 4.813